Search Results

Mithra, a company dedicated to women’s health, announces that in the context of the monetization process and the uncertainties related thereto, Mithra postpones its Annual General Shareholders’ Meeting, previously planned for 30 May 2024, to a later date to be determined.

Mithra, a company dedicated to Women’s Health, announces that it has been granted an additional patent for NEXTSTELLIS® tablets) in the United States.

Mithra, a company dedicated to women’s health, provides an update on its current cash position and its plans to address its runway and creating and optimizing value for all its stakeholders.

Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the completion of a pediatric study of its marketed contraceptive ESTELLE® in adolescent women.

Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the signing of a binding Head of Terms (HoT) agreement for the commercialization of DONESTA® in Israel with Rafa Laboratories LTD, an Israeli pharmaceutical company.

Mithra and Searchlight Pharma Sign DONESTA ® Licensing Agreement for Canada.

Mithra announces that the US Food and Drug Administration has provided feedback regarding its new drug application marketing authorization filing in the United States.

Mithra announced the signing of a binding term sheet for a licensing agreement for the Canadian rights to Donesta®, an investigational medicine for the treatment of the symptoms of menopause.

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA are pleased to announce NEXTSTELLIS® has been nominated for the 2022 Prix Galien USA Award for Best Pharmaceutical Agent.

First E4-based product approved internationally Canadian regulatory approval is the first in the world for the novel combined oral contraceptive Nextstellis ® Innovative product developed by Mithra containing the unique native estrogen Estetrol (E4) and drospirenone (DRSP) Approval supported by two large multinational Phase 3 studies conducted in 3,725 women